back
Biomedical

Genesis Of A Gene Therapy Manufacturing Giant

Forge Biologic’s recent financing round turned out to be the largest Series B fundraise in Ohio’s history.

Jul 20, 2021 // By Matthew Pillar // BioProcess

Dr. Timothy Miller is leading an effort to build one of the world’s largest AAV gene therapy manufacturing facilities. The co-founder and CEO of Columbus, OH-based Forge Biologics has been scratching the regenerative medicine leadership itch for quite a while now. After a few years in the lab at Copernicus Therapeutics and Juventas Therapeutics, and a few more as product development lead at SironRX, he spent nearly seven years at the helm of Abeona Therapeutics after founding that company. If all that experience with clinical-stage organizations taught him anything, it’s that one key to longevity is a quick path to an elusive thing among clinical-stage biotechs: revenue.

When Forge Biologics was launched in 2020, therapeutics development was Dr. Miller’s vision as it has been throughout his career. What he sought, however, was to build an organization that could quickly achieve revenue. That is a tall order for a company focused exclusively on novel gene therapy development, where the timeline to revenue is typically measured in decades. To comfortably fuel its own pipeline, Forge would need a revenue engine.

That’s why, when he and his team of co-founders and investors dreamed up the company’s hub-and-spoke business model, they leaned heavily into something else they’d all learned along their journeys: gene therapy manufacturing.

Read the full article.


Tags

Article // Biomedical // biomedical // biosciences // Gene Therapy // gene therapy research // gene therapy studies // genetic innovation // genetic research // Healthcare